Collplant biotechnologies reports 2023 full year financial results and provides corporate update

Dermal filler program with abbvie in clinical phase regenerative breast implant program large-animal study underway to evaluate commercial-size implants with topline data expected in q4 ends 2023 with $26.7 million in cash and cash equivalents conference call to be held on thursday, april 4, 2024 at 10:00 a.m. u.s. edt  rehovot, israel, april 4, 2024 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhcollagen) for tissue regeneration and organ manufacturing, today announced financial results for the full year ended december 31, 2023 and provided a corporate update.
CLGN Ratings Summary
CLGN Quant Ranking